JPS60253442A - Treatment of motion disease of horse - Google Patents

Treatment of motion disease of horse

Info

Publication number
JPS60253442A
JPS60253442A JP10765084A JP10765084A JPS60253442A JP S60253442 A JPS60253442 A JP S60253442A JP 10765084 A JP10765084 A JP 10765084A JP 10765084 A JP10765084 A JP 10765084A JP S60253442 A JPS60253442 A JP S60253442A
Authority
JP
Japan
Prior art keywords
germanium
horse
semiconductor
piece
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10765084A
Other languages
Japanese (ja)
Inventor
亨 濱田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAMADA IKEN KK
Original Assignee
HAMADA IKEN KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAMADA IKEN KK filed Critical HAMADA IKEN KK
Priority to JP10765084A priority Critical patent/JPS60253442A/en
Priority to GB08512852A priority patent/GB2159411A/en
Priority to AU42769/85A priority patent/AU4276985A/en
Priority to DE19853519083 priority patent/DE3519083A1/en
Priority to FR8508042A priority patent/FR2565106A1/en
Publication of JPS60253442A publication Critical patent/JPS60253442A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。
(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

【発明の詳細な説明】 〔産業上の利用分野〕 この発明は、例えば競走馬の運動器疾患の治療法に関す
るものである。
DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a method for treating locomotor diseases of racehorses, for example.

〔従来の技術とその問題点〕[Conventional technology and its problems]

競走馬は、競走を目的とし日常過度の運動を負荷してお
り、このため競走馬の疾患は大半が運動諸系にあり、そ
のなかでも筋肉系、展、関節系の疾患が大部分を占めて
いる。
Racehorses are subjected to excessive exercise on a daily basis for the purpose of racing, and for this reason, most of the diseases in racehorses are related to the movement system, and among these, diseases of the muscular system, extension, and joint system account for the majority. ing.

これ等の治療には、休養が最適と言われているが現実に
は困難なことが多く、薬物を投与しながら出走させてい
るのが実情である。しかし、これ等の疾患も慢性化する
と薬物による治療だけでは効果が得られない場合が多く
、鍼灸療法と併用している例が多い。
Rest is said to be the best treatment for these conditions, but in reality this is often difficult, and the reality is that the animals are given drugs while running. However, when these diseases become chronic, drug treatment alone is often ineffective, and acupuncture and moxibustion therapy are often used together.

更に、競走馬には日常の健康管理が重要であり、予防獣
医学的な立場からも馬体や筋肉、昶等の疲労を早期に取
り除き、以上の疾患予防に務めなければならないが、こ
れ等に対する適当な予防法が現在までのところ見出され
ていない。
Furthermore, daily health management is important for racehorses, and from a preventive veterinary standpoint, it is necessary to eliminate fatigue in the horse's body, muscles, and muscles as soon as possible to prevent the above-mentioned diseases. No suitable preventive method has been found to date.

この発明は、上記実情に鑑み例えば競走馬等或いはこれ
等の予防法を、提案するものである。
In view of the above-mentioned circumstances, the present invention proposes, for example, racehorses and a preventive method thereof.

〔発明の要旨〕[Summary of the invention]

この発明の要旨は、馬の疾患箇所或いは経穴にゲルマニ
ウム半導体を主成分とする尚接片を接着させて治療を行
うものである。
The gist of this invention is to treat a horse by adhering a patch containing germanium semiconductor as its main component to a diseased area or acupuncture point.

即ち、ゲルマニウム半導体は他の金属と異なる特異な半
導体特性を有することが知られているが、この発明によ
ればこのようなゲルマニウム半導体を主成分とする当接
片を使用することにより競走馬等の筋肉系、鍵、関節系
の疾患に治療効果或いは予防効果のあることを見出した
ものである。
That is, it is known that germanium semiconductors have unique semiconductor properties different from those of other metals, and according to the present invention, by using a contact piece whose main component is germanium semiconductors, racehorses, etc. It has been discovered that this drug has a therapeutic or preventive effect on diseases of the muscular system, keys, and joint system.

ここでゲルマニウム半導体を主成分とする当接片として
は、例えば(a)高純度、例えば純度99゜99%のゲ
ルマニウム金属を使用したもの、(b)ゲルマニウム半
導体と、他の半導体例えばシリコン、セレン°、テルル
、ホウ素等とを混合したもの、(c)純粋なゲルマニウ
ムに+5または+3の原子価をもつ不純物を付は加えて
N型またはP型の半導体としたもの、(d)ゲルマニウ
ム粉粒と活性炭粉末の混合物を焼結等により加熱成形処
理したもの、(g)ゲルマニウム粉粒と、熱伝導性が良
好であってイオン化しにくい金属粉粒、例えば銀、金、
錫、アルミニウム、銅との混合物を焼結等により加熱成
形処理したもの、(ハ上記(α)〜(6)の上に銀、金
による薄膜を施したもの等を挙げることができる。
Here, the contact piece whose main component is germanium semiconductor may be (a) one using germanium metal of high purity, for example, 99.99% purity, or (b) one using germanium semiconductor and other semiconductors such as silicon or selenium. (c) pure germanium with or without impurities with a valence of +5 or +3 added to make it an N-type or P-type semiconductor; (d) germanium powder (g) germanium powder and metal powder that has good thermal conductivity and is difficult to ionize, such as silver, gold,
Examples include those obtained by heat-forming a mixture of tin, aluminum, and copper by sintering or the like, and those obtained by applying a thin film of silver or gold on the above (α) to (6).

ここで(6)の場合はゲルマニウム半導体が少なくとも
60重量であり、更に(d)の加熱成形したものは、ゲ
ルマニウム半導体の半導体特性による効果の他に、物理
的刺激原動も得られる。この場合ゲルマニウム粉粒と活
性炭粉末の混合比はこれ等の体積比で前者40〜70%
、後者60〜30%が好ましい。
In the case of (6), the germanium semiconductor has a weight of at least 60%, and the heat-formed product of (d) also provides a physical stimulation motive force in addition to the effect due to the semiconductor properties of the germanium semiconductor. In this case, the mixing ratio of germanium powder and activated carbon powder is 40 to 70% by volume of the former.
, the latter is preferably 60 to 30%.

またta>のゲルマニウム粉粒と熱伝導性が良好であっ
てイオン化しにくい金属粉粒との混合割合は特に限定さ
れないが、ゲルマニウム粉粒が好ましくは20重JIX
以上、最も好ましくは50重量%以上である。20重量
%以上であれば、当接片ノケルマニウム半導体特性が失
われることがない。また、20重量に以下ではゲルマニ
ウム半導体による所期の効果が低下する。
In addition, the mixing ratio of germanium powder particles of ta> and metal powder particles that have good thermal conductivity and are difficult to ionize is not particularly limited, but germanium powder particles are preferably 20-weight JIX
More preferably, it is 50% by weight or more. If the content is 20% by weight or more, the contact piece's nokermanium semiconductor properties will not be lost. Further, below 20% by weight, the desired effect of the germanium semiconductor decreases.

更に、この発明に使用するゲルマニウム半導体は単結晶
でも、多結晶でもよい。
Furthermore, the germanium semiconductor used in this invention may be single crystal or polycrystalline.

一方、この発明に使用する当接片は疾患或いは経穴等の
部位に接着し易いものであれば、その形状等は限定され
ないが、第1,2図に示すように例えば高さ4簡の円柱
部/と、該円柱部lの上面に形成された高さ1m+の円
錐部λとがらなり、上記円錐部2の表面全周にはその頂
部−αに集束する三角形状のテーパー面3・・・を′連
設するようにした形状のものが好ましい。
On the other hand, the shape of the abutting piece used in this invention is not limited as long as it can easily adhere to areas such as diseases or acupuncture points, but as shown in Figs. and a conical part λ having a height of 1 m+ formed on the upper surface of the cylindrical part l, and a triangular tapered surface 3 converging at the apex -α on the entire surface of the conical part 2... It is preferable to have a shape in which these are connected in series.

なお、この場合円柱部lの径は接着場所によって異なり
、例えば膝の場合は15 m S臀部の場合は20II
II+1足首等の細い部分には10m程度のものが好ま
しい。
In addition, in this case, the diameter of the cylindrical part l varies depending on the bonding location, for example, 15 m for the knee and 20 mm for the buttock.
For narrow parts such as II+1 ankles, a length of about 10 m is preferable.

また、第3図は、第1,2図の変形で、この場合上記三
角形状のテーパー面3′はその稜線3α′、3α′を多
少螺旋状にして円錐部λの頂部2α状でもよい。
Further, FIG. 3 is a modification of FIGS. 1 and 2, in which case the triangular tapered surface 3' may have its ridge lines 3α', 3α' somewhat spiraled to form the apex 2α of the conical portion λ.

以上のような当接片は、馬の疾患部或いは経穴等に接着
されるが、第2,3図に示す当接片を使用した場合には
円錐部λの頂部2αを疾患部或いは経穴等に当接し、更
に絆創膏等の皮接片を用いて固定する。
The contact piece described above is attached to the diseased area or acupuncture point of the horse, but when the abutment piece shown in Figs. 2 and 3 is used, the top 2α of the conical part and then fix it using a skin patch such as a bandage.

この場合、この実施例では円錐部コの表面全周に三角形
状のテーパー面3・・・、或いは多少螺旋状の三角形状
のテーパー面3′・・・を連設しであるため、円錐部2
が馬の疾患部或いは経穴等に食い込み、効果的な治療を
行うことができる。
In this case, in this embodiment, a triangular tapered surface 3... or a somewhat spiral triangular tapered surface 3'... is continuously provided on the entire surface of the conical portion. 2
It penetrates into the horse's diseased areas or acupuncture points, allowing for effective treatment.

〔実施例〕〔Example〕

1、 試験馬 山形系上山競馬場で競走に出走している競走馬7頭を試
験馬とした。うち筋肉痛を呈しているもの5頭、関節炎
を呈しているもの2頭とし、筋肉痛群と関節炎群の2群
に分類した。いずれもサラ種4〜8才、雌3頭、雄4頭
である(下記表1、表2)。
1. Test Horses Seven racehorses running in the Yamagata-based Kaminoyama Racecourse were used as test horses. Of these, 5 dogs had muscle pain and 2 dogs had arthritis, and they were classified into 2 groups: myalgia group and arthritis group. All of them are Sara breeds, 4 to 8 years old, 3 females and 4 males (Tables 1 and 2 below).

表1. 筋肉痛群 表λ 関節炎群 λ 試験方法 第1,2図に示す当接片を筋肉痛群では前部で肩囲(α
)、槍風(b)、衝天(c)、後編では腎棚(4)、腎
角(a)、口出(ハ、汗溝(a)、後伏兎(A)の経穴
を選び左右各々1ケずつ接着した(第4図参照)。
Table 1. Myalgia group table λ Arthritis group λ Test method The abutment piece shown in Figures 1 and 2 was attached to the shoulder circumference (α
), Yarifu (b), Shouten (c), and in the second part select the acupuncture points of Kidney Shelf (4), Kidney Corner (a), Kuchide (Ha), Sweat Groove (a), and Gofuusagi (A) for each side. I glued them one by one (see Figure 4).

関節炎群では内外側に各々2ケずつ接着した(第5図参
照)。
In the arthritis group, two pieces were glued each on the inner and outer sides (see Figure 5).

調教時には、当接片を取り外し、終了時に汗などの水分
を充分拭き取り、再び同じ部位に貼り付けた。
At the time of training, the contact piece was removed, and when the training was finished, moisture such as sweat was thoroughly wiped off and the piece was pasted on the same area again.

また、被電部分iに当接片を貼り付ける場合には当接片
を貼り付ける部分jのみを刷毛し、その周囲を絆創膏等
で固定して離脱しないようにした。
Further, when attaching the abutting piece to the electrified part i, only the part j to which the abutting piece is to be attached was brushed, and the area around it was fixed with a bandage or the like to prevent it from coming off.

更に、関節に当接片を接着する際には接着したその上に
環軸包帯弘を施し離脱しないようにした(第6図参照)
Furthermore, when adhering the abutment piece to the joint, an atlantoaxial bandage was applied over the adhered piece to prevent it from coming off (see Figure 6).
.

なお、以上の試験期間はそれぞれ約1ケ月間とした。Note that each of the above test periods was approximately one month.

3、 臨床結果 筋肉痛群の臨床結果を、筋の緊張、筋の圧痛、多様in
眼に区分し、また関節炎群の臨床結果を腫脹、熱感、圧
痛に分け、且つそれぞれを著効、有効、や\有効、無効
の四段階に分けてその効果を検討した。
3. Clinical results The clinical results of the muscle pain group were examined in terms of muscle tension, muscle tenderness, and various types of pain.
The clinical results of the arthritis group were divided into swelling, warmth, and tenderness, and the effects of each were divided into four stages: excellent, effective, moderately effective, and ineffective.

α、筋肉痛群の臨床効果は、筋の緊張緩和が有効が4頭
、無効が1頭、筋の圧痛の緩和が有効3頭、や\有効1
頭、無効1頭、歩様鎗眼の消失かや\有効3頭、無効2
頭であった(表3)。
α, The clinical effects for the muscle pain group are as follows: 4 patients found that muscle tension relief was effective, 1 patient said it was ineffective, 3 patients found that muscle tenderness relief was effective, and \effective 1 patient.
Head, 1 invalid, missing gait and gait \ 3 valid, 2 invalid
It was the head (Table 3).

表3. 筋肉群の臨床所見側による効果す、関節炎群の
臨床効果は、腫脹の緩和がやや有効2頭、熱感の緩和か
や\有効2″頭、圧痛の消失がや\有効1頭、無効1頭
であった(表4)。
Table 3. The clinical effects of the arthritis group were slightly effective in reducing swelling (2 cases), relief of heat sensation (2 cases), relief of tenderness (2 cases), disappearance of tenderness (1 case), and 1 case (ineffective). It was the head (Table 4).

4、結論 以上の臨床効果より次のような結論を導ひくことができ
る。即ち、 a、筋肉痛群に対しては、筋肉の緊張や筋圧痛の緩和が
認められ、したがってこの発明による方法は運動による
筋肉疲労が蓄積して緊張し疼痛を呈する様な場合に効果
がある。
4. Conclusion The following conclusions can be drawn from the above clinical effects. That is, a. Relief of muscle tension and muscle tenderness was observed in the muscle pain group, and therefore, the method according to the present invention is effective in cases where muscle fatigue due to exercise accumulates and tenses up and causes pain. .

b、関節炎群については、腫脹や熱感の緩和が認められ
た。
b. In the arthritis group, relief of swelling and hot sensation was observed.

〔発明の効果〕〔Effect of the invention〕

以上要するに、この発明によれば馬の筋肉系、鍵、関節
系等の疾患治療に効果があり、また競走馬等においては
蓄積された疲労が疾病の発生要因になり易いが、この発
明によれば羅患する以前の疲労回復にも著効があるので
、以上の疾患に対する予防的効果もある。
In summary, this invention is effective in treating diseases of horses' muscular systems, locks, joints, etc., and in racehorses, etc., accumulated fatigue tends to be a cause of diseases. It is also effective in recovering from fatigue before contracting the disease, so it also has a preventive effect against the above-mentioned diseases.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図はこの発明で使用する当接片の一側面図、第2図
は同上の平面図、第3図は当接片の他の実施例を示す平
面図、第4図は筋肉痛群における馬体の当接片接着部位
の一例を示す図、第5図は関節炎群における馬体の当接
片接着部位の一例を示す図、第6図は当接片の接着法の
一例を示す図である。 特許出願人 株式会社ハマ ダ医研′ 箇、1111 $1211 第3図 M6図
Fig. 1 is a side view of the abutment piece used in this invention, Fig. 2 is a plan view of the same as above, Fig. 3 is a plan view showing another embodiment of the abutment piece, and Fig. 4 is a muscle pain group. Fig. 5 is a diagram showing an example of the adhesion site of the abutment piece on the horse's body in the arthritic group, and Fig. 6 is an example of the method of adhering the abutment piece. It is a diagram. Patent applicant Hamada Iken Co., Ltd., 1111 $1211 Figure 3 M6

Claims (4)

【特許請求の範囲】[Claims] (1)馬の疾患箇所或いは経穴にゲルマニウム半導体を
主成分とする当接片を接着することを特徴とする馬の運
動器疾患治療法。
(1) A method for treating musculoskeletal diseases in horses, which comprises adhering a contact piece containing germanium semiconductor as a main component to diseased areas or acupuncture points in horses.
(2)予防を目的として行う特許請求の範囲第1項記載
の方法。
(2) The method according to claim 1, which is carried out for the purpose of prevention.
(3) 当接片がゲルマニウム半導体と、他の半導体と
を混合したものからなる特許請求の範囲第1項記載の方
法。
(3) The method according to claim 1, wherein the contact piece is made of a mixture of a germanium semiconductor and another semiconductor.
(4) 当接片がゲルマニウム粉粒と、活性炭粉末或い
は熱伝導性が良好であってイオン化しにくい金属粉粒を
焼結等により加熱成形処理したものである特許請求の範
囲第1項記載の方法。
(4) The abutting piece is made of germanium powder and activated carbon powder or metal powder that has good thermal conductivity and is difficult to ionize and is heat-formed by sintering or the like. Method.
JP10765084A 1984-05-29 1984-05-29 Treatment of motion disease of horse Pending JPS60253442A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP10765084A JPS60253442A (en) 1984-05-29 1984-05-29 Treatment of motion disease of horse
GB08512852A GB2159411A (en) 1984-05-29 1985-05-21 Cure of locomotorial disease in horses
AU42769/85A AU4276985A (en) 1984-05-29 1985-05-22 Cure of locomotorial disease in horses
DE19853519083 DE3519083A1 (en) 1984-05-29 1985-05-28 METHOD AND DEVICE FOR TREATING A DISEASE IN A MOVEMENT ORGAN OF A HORSE
FR8508042A FR2565106A1 (en) 1984-05-29 1985-05-29 BUFFER ESSENTIALLY FORMED OF GERMANIUM FOR TREATMENT TO TREAT LOCOMOTRIC DISEASES OF HORSES AND METHOD OF USE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10765084A JPS60253442A (en) 1984-05-29 1984-05-29 Treatment of motion disease of horse

Publications (1)

Publication Number Publication Date
JPS60253442A true JPS60253442A (en) 1985-12-14

Family

ID=14464563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10765084A Pending JPS60253442A (en) 1984-05-29 1984-05-29 Treatment of motion disease of horse

Country Status (5)

Country Link
JP (1) JPS60253442A (en)
AU (1) AU4276985A (en)
DE (1) DE3519083A1 (en)
FR (1) FR2565106A1 (en)
GB (1) GB2159411A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU184575B (en) * 1982-07-16 1984-09-28 Otto Mallasz Method for producing preparations fixable on skin generating locally electrolytic and bio currents
CA2076574A1 (en) * 1991-10-01 1993-04-02 John Lenneis Haynes Extended-life drug filled patch

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5558170A (en) * 1978-10-25 1980-04-30 Tooru Hamada Treatment piece for skin contact
JPS5611815B2 (en) * 1975-08-08 1981-03-17
JPS5848186A (en) * 1981-09-17 1983-03-22 株式会社東芝 Ticketing machine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5611815B2 (en) * 1975-08-08 1981-03-17
JPS5558170A (en) * 1978-10-25 1980-04-30 Tooru Hamada Treatment piece for skin contact
JPS5848186A (en) * 1981-09-17 1983-03-22 株式会社東芝 Ticketing machine

Also Published As

Publication number Publication date
FR2565106A1 (en) 1985-12-06
GB2159411A (en) 1985-12-04
DE3519083C2 (en) 1988-04-14
GB8512852D0 (en) 1985-06-26
AU4276985A (en) 1985-12-05
DE3519083A1 (en) 1986-04-17

Similar Documents

Publication Publication Date Title
Maughan et al. Incidence of training-related injuries among marathon runners.
US4592912A (en) Ache and pain relieving and preventing composition
Marks Medical management of back pain
JPS6115703B2 (en)
JPS60253442A (en) Treatment of motion disease of horse
US6146639A (en) Arthritis, muscle pain, and dry skin remedy
TRIPOLI et al. Muscular Dystrophy and Atrophy: Clinical and Biochemical Results Following the Oral Administration of Amino-Acids
Smith et al. Zoxazolamine (Flexin) in rheumatic diseases: Preliminary report
Barone Topical analgesics: how effective are they?
Mead et al. Topical Cryotherapy—Use for Relief of Pain and Spasticity
Jean-Pierre Hourdebaigt Equine Massage: A practical guide
RU2101015C1 (en) External agent and a method of treatment of neurological and locomotor system disorders in combination with the pain syndrome and edema
WO1996032952A1 (en) Caffeine composition as medicament and use thereof
EP2524683A1 (en) Kinesio tape
Feraboli Apitherapy in orthopaedic diseases
JPH03184915A (en) Method for relaxing menorrhalgia
Murrell Massage as a Mode of Treatment
RU2182006C2 (en) Method to treat rheumatoid arthritis
Nishioka et al. Scorpion sting on the penis
James et al. Diagnosis and treatment of a fractured third phalanx in a Masai giraffe (Giraffe camelopardalis tippelskirchi)
Watt The toxic effects of the bite of a clubionid spider
Debouzy et al. Antalgic Properties of Millimetric Waves on Chronical Pain: Is It Possible to Distinguish between Neuroplastic and Neuropathic Pain? A Report About 2 Fibromyalgia Cases
JP5348894B2 (en) Soap fragrance patch and treatment of muscle spasms and pain
Kognole et al. Intravenous regional anaesthesia of forelimb using bupivacaine, pentazocine, ketamine and buprenorphine alone or in
Edgell The holistic horse: Alternative therapies for equine health